The DOI matches its Crossref record.
Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML
Open accessAbstract
Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia (AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely treatment adjustments to preempt relapse. Current surveillance techniques detect circulating blasts that coincide with advanced disease and poorly reflect MRD during early relapse. Here, we investigate exosomes as a minimally invasive platform for a microRNA (miRNA) biomarker. We identify a set of miRNA enriched in AML exosomes and track levels of circulating exosome miRNA that distinguish leukemic xenografts from both non-engrafted and human CD34+ controls. We develop biostatistical models that reveal circulating exosomal miRNA at low marrow tumor burden and before circulating blasts can be detected. Remarkably, both leukemic blasts and marrow stroma contribute to serum exosome miRNA. We propose development of serum exosome miRNA as a platform for a novel, sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Doyle, L., & Wang, M. (2019) · Cells · doi:10.3390/cells8070727 · Cited by 3,236
Exosome-Mediated Metastasis: Communication from a Distance
Wortzel, I., Dror, S., Kenific, C. M., & Lyden, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.011 · Cited by 1,285
Haraszti, R. A., Didiot, M., Sapp, E., Leszyk, J., Shaffer, S. A., Rockwell, H. E., Gao, F., Narain, N. R., DiFiglia, M., Kiebish, M. A., et al. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.32570 · Cited by 746
Brites, D., & Fernandes, A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00476 · Cited by 599
“Exosomal miRNAs have been indicated as a promising platform for compartment biomarker and early detection of diseases, including brain disorders (Cheng et al., 2014; Khalyfa and Gozal, 2014; Hornick et al., 2015; Lin et al., 2015; Schwarzenbach, 2015).”
BackgroundThe biology, function, and applications of exosomes in cancer
Liu, J., Ren, L., Li, S., Li, W., Zheng, X., Yang, Y., Fu, W., Yi, J., Wang, J., & Du, G. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.001 · Cited by 561
Role of exosomal proteins in cancer diagnosis
Li, W., Li, C., Zhou, T., Liu, X., Liu, X., Li, X., & Chen, D. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0706-8 · Cited by 447
MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression
Teng, Y., Ren, Y., Hu, X., Mu, J., Samykutty, A., Zhuang, X., Deng, Z., Kumar, A., Zhang, L., Merchant, M. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms14448 · Cited by 408
Exosomal miRNAs as cancer biomarkers and therapeutic targets
Thind, A., & Wilson, C. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.31292 · Cited by 404
Exosomes in Cancer Diagnostics
Soung, Y., Ford, S., Zhang, V., & Chung, J. (2017) · Cancers · doi:10.3390/cancers9010008 · Cited by 368
Gao, N., Li, Y., Li, J., Gao, Z., Yang, Z., Li, Y., Liu, H., & Fan, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.598817 · Cited by 304
Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?
Ratajczak, M. Z., & Ratajczak, J. (2020) · Leukemia · doi:10.1038/s41375-020-01041-z · Cited by 294
Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment
Tian, X., Shen, H., Li, Z., Wang, T., & Wang, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0772-z · Cited by 264
Tang, Y., Cui, Y., Li, Z., Jiao, Z., Zhang, Y., He, Y., Chen, G., Zhou, Q., Wang, W., Zhou, X., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0285-3 · Cited by 152
Biogenesis, Isolation, and Detection of Exosomes and Their Potential in Therapeutics and Diagnostics
Sonbhadra, S., Mehak, & Pandey, L. M. (2023) · Biosensors · doi:10.3390/bios13080802 · Cited by 97
Metadata
- Authors
- Hornick, N. I., Huan, J., Doron, B., Goloviznina, N. A., Lapidus, J., Chang, B. H., & Kurre, P.
- Venue
- Scientific Reports
- Published
- 2015-06-12
- Volume
- 5
- Issue
- 1
- Pages
- 11295-11295
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2256328335
- Cited by
- 247
- References
- 0
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.